Akèy › Kansè nan tete › Kalifòni › Mountain View
Etid klinik pou Kansè nan tete nan Mountain View, CA
26 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Mountain View (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- Stanford Women's Cancer Center, Palo Alto · 5 mi lwen
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- Stanford University School of Medicine, Palo Alto · 5 mi lwen
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- El Camino Hospital, Mountain View
- Palo Alto Medical Foundation, Mountain View
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Ap rekriteFaz 1/2
- Stanford Medicine Cancer Center, Stanford · 5 mi lwen
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- El Camino Hospital Cancer Center ( Site 0096), Mountain View
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- Stanford University Medical Center, Stanford · 5 mi lwen
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- Stanford University Medical Center, Stanford · 5 mi lwen
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- Stanford Cancer Center, Palo Alto · 5 mi lwen
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center, Palo Alto · 5 mi lwen
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Stanford Women's Cancer Center, Palo Alto · 5 mi lwen
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Ap rekriteFaz 1
- Stanford University Hospital, Stanford · 5 mi lwen
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Ap rekriteFaz 3
- Research Site, Palo Alto · 5 mi lwen
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Ap rekriteFaz 2
- Stanford Cancer Institute, Palo Alto · 5 mi lwen
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- Palo Alto Medical Foundation Research Center, Palo Alto · 5 mi lwen
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi lwen
- ak 1 plis
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Ap rekriteFaz 2
- Stanford University, Stanford · 5 mi lwen
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Local Institution - 0358, Stanford · 5 mi lwen
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- Stanford Medicine Cancer Center - Stanford Women's Cancer Center, Palo Alto · 5 mi lwen
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Ap rekriteFaz 1
- Stanford University Medical Center, Palo Alto · 5 mi lwen
Magnetic Resonance Imaging of Breast Cancer
Ap rekriteVolontè an sante akeyi
- Stanford University School of Medicine, Stanford · 5 mi lwen
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Ap rekriteEtid obsèvasyon
- Stanford University School of Medicine, Stanford · 5 mi lwen
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi lwen
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi lwen
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Ap rekriteFaz 1
- Stanford Cancer Institute, Stanford · 5 mi lwen
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
Ap rekrite
- Stanford University, Stanford · 5 mi lwen
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Ap rekriteEtid obsèvasyon
- Stanford Cancer Institute, Palo Alto · 5 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Stanford · 5 mi lwen
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Mountain View
- Kansè (tout kalite)40 etid
- Kansè Metastatik25 etid
- Kansè Poumon ki pa ti selil21 etid
- Leksemi mieloïd egi19 etid
- Kansè ovè19 etid
- Twoub Spektòm Otis17 etid
- Kansè poumon17 etid
- Kansè pwostat15 etid
- Ensifizyans kadyak15 etid
- Otis13 etid
- Leksemi limfoblastik egi13 etid
- Kansè kolorektal13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.